BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
Carlos Pérez-Monter, Aldo Torre-Delgadillo. Astrocyte - Physiology and Pathology2018;  doi: 10.5772/intechopen.72506
2
P. D. J. Dunne, J. A. Fallowfield. Editorial: getting bullish about portal hypertension-chronic treatment with oral taurine?Alimentary Pharmacology & Therapeutics 2018; 47(4): 533 doi: 10.1111/apt.14444
3
Harikumar Nair, Annalisa Berzigotti, Jaime Bosch. Emerging therapies for portal hypertension in cirrhosisExpert Opinion on Emerging Drugs 2016; 21(2): 167 doi: 10.1080/14728214.2016.1184647
4
Xing-Qiu Liang, Jian Liang, Xiao-Fang Zhao, Xin-Yuan Wang, Xin Deng. Integrated network analysis of transcriptomic and protein-protein interaction data in taurine-treated hepatic stellate cellsWorld Journal of Gastroenterology 2019; 25(9): 1067-1079 doi: 10.3748/wjg.v25.i9.1067
5
Qinglu Xu, Tianzhu Luan, Songbin Fu, Jian Yang, Chao Jiang, Fangfang Xia. Effects of Pitavastatin on the Expression of VCAM-1 and its Target Gene miR-126 in Cultured Human Umbilical Vein Endothelial CellsCardiovascular Therapeutics 2014; 32(5): 193 doi: 10.1111/1755-5922.12081
6
R. Schwarzer, D. Kivaranovic, M. Mandorfer, R. Paternostro, D. Wolrab, B. Heinisch, T. Reiberger, M. Ferlitsch, C. Gerner, M. Trauner, M. Peck-Radosavljevic, A. Ferlitsch. Randomised clinical study: the effects of oral taurine 6g/day vs placebo on portal hypertensionAlimentary Pharmacology & Therapeutics 2018; 47(1): 86 doi: 10.1111/apt.14377
7
Jordi Gracia-Sancho, Giusi Marrone, Anabel Fernández-Iglesias. Hepatic microcirculation and mechanisms of portal hypertensionNature Reviews Gastroenterology & Hepatology 2019; 16(4): 221 doi: 10.1038/s41575-018-0097-3
8
Hongyue Ma, Jiejun Jiang, Junfeng Zhang, Jing Zhou, Anwei Ding, Gaohong Lv, Huiqin Xu, Fenqiang You, Zhen Zhan, Jinao Duan. Protective effect of taurine on cardiotoxicity of the bufadienolides derived from toad (Bufo bufo gargarizansCanto) venom in guinea-pigsin vivoandin vitroToxicology Mechanisms and Methods 2012; 22(1): 1 doi: 10.3109/15376516.2011.583295
9
Marina Vilaseca, Sergi Guixé-Muntet, Anabel Fernández-Iglesias, Jordi Gracia-Sancho. Advances in therapeutic options for portal hypertensionTherapeutic Advances in Gastroenterology 2018; 11: 175628481881129 doi: 10.1177/1756284818811294
10
Natural Sulfur-Containing Compounds: An Alternative Therapeutic Strategy against Liver FibrosisCells 2019; 8(11): 1356 doi: 10.3390/cells8111356
11
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma, Jing-Yuan Fang. Dynamic expression of miR-126∗and its effects on proliferation and contraction of hepatic stellate cellsFEBS Letters 2013; 587(23): 3792 doi: 10.1016/j.febslet.2013.09.047
12
Johannes Wiegand, Florian van Bömmel, Andrés Duarte-Rojo, José Altamirano, Juan G. Abraldes, Augusto Villanueva, Thomas Berg. Clinical Trial Watch: Reports from the Liver Meeting®, AASLD, San Francisco, November 2015Journal of Hepatology 2016; 64(6): 1428 doi: 10.1016/j.jhep.2016.02.020
13
Can-Jie Guo, Qin Pan, Hua Xiong, Yu-Qi Qiao, Zhao-Lian Bian, Wei Zhong, Li Sheng, Hai Li, Lei Shen, Jing Hua, Xiong Ma. Therapeutic Potential of MicroRNA: A New Target to Treat Intrahepatic Portal Hypertension?BioMed Research International 2014; 2014: 1 doi: 10.1155/2014/797898
14
Philipp Schwabl, Wim Laleman. Novel treatment options for portal hypertensionGastroenterology Report 2017; 5(2): 90 doi: 10.1093/gastro/gox011
15
Asbjørn Gildberg, Jan Arne Arnesen, Bjørn-Steinar Sæther, Jaran Rauø, Even Stenberg. Angiotensin I-converting enzyme inhibitory activity in a hydrolysate of proteins from Northern shrimp (Pandalus borealis) and identification of two novel inhibitory tri-peptidesProcess Biochemistry 2011; 46(11): 2205 doi: 10.1016/j.procbio.2011.08.003